Should California Employers Still Test for THC in 2027?
California legalized recreational cannabis, then passed AB 2188 and SB 700 to restrict how employers can use THC test results. So where does that leave your drug testing program? The answer is not simple — and it is not the same for every employer in the state.
Quick Answer
It depends on your industry and your legal status. California construction employers may still test for THC — they are explicitly exempt from AB 2188. DOT-regulated and federal contractors must test for THC under federal law. Most private California employers outside those categories cannot take adverse employment action based solely on a positive urine or hair THC metabolite result under AB 2188 and SB 700. For those employers, the practical options are: remove THC from the urine panel, switch to non-THC drug testing supplies, or use oral fluid saliva testing for scenarios where current impairment — not past use — is what matters.
What AB 2188 and SB 700 Actually Changed
Before 2024, California employers could generally screen for THC as part of a pre-employment or workplace drug testing panel and act on a positive result. AB 2188 and SB 700, both effective January 1, 2024, changed that framework in two critical ways.
AB 2188 amended the California Fair Employment and Housing Act to prohibit employers from discriminating against employees or applicants based on their off-duty, off-premises cannabis use. More specifically, it prohibits adverse employment action based on a positive test for non-psychoactive cannabis metabolites — the THC-COOH compounds detected by standard urine and hair immunoassay panels. The law draws a sharp distinction: detecting a metabolite tells an employer that an employee used cannabis at some point in the past, not that they were impaired during working hours.
SB 700 extended those protections to the pre-employment context, prohibiting employers from asking applicants about prior cannabis use and from using pre-employment urine or hair THC metabolite results as grounds for declining to hire.
California state employees are governed separately. The California Department of Human Resources administers a controlled substance testing program for state civil service positions that operates under its own authority — information available through CalHR. Those employees are not covered by AB 2188's private-employer restrictions.
⚠ What AB 2188 does NOT prohibit: Employers may still prohibit cannabis use and impairment during work hours and on company property. They may discipline or terminate an employee who is visibly impaired at work by cannabis. They may use oral fluid saliva testing — which detects the parent drug compound rather than metabolites — to test for recent impairment. The law restricts what test results can be used for, not the existence of a drug testing program.
California THC Testing Authority by Employer Type — 2027
The Metabolite Problem: Why Standard Urine THC Tests Create Legal Risk
The core issue with urine THC testing for California private employers is biological, not political. THC-COOH — the metabolite detected by standard immunoassay urine panels — is a storage metabolite that accumulates in fat tissue and is released slowly over time. Its presence in urine has no established relationship to current impairment. A regular cannabis user can test positive on a urine THC panel for 30 days or more after their last use, long after any psychoactive effect has passed.
What AB 2188 recognized is that acting on that result — declining to hire, or terminating employment — penalizes off-duty behavior that the California Legislature has determined is legal and protected. The same logic does not apply to cocaine, methamphetamine, opioids, or benzodiazepines, which is why AB 2188 is narrowly targeted at cannabis metabolites and does not restrict testing for other substances.
For California private employers in non-exempt categories, keeping THC on the urine panel generates a result that cannot support adverse employment action under AB 2188 — which means the test creates legal exposure without producing actionable information. That is the central reason so many California employers have made the practical decision to remove THC from their urine panel.
Three Practical Paths for California Employers in 2027
Path 1 — Remove THC from the Urine Panel
The most straightforward adaptation is to drop THC from the urine testing panel for non-exempt employee classifications. Non-THC drug test kits for employers are available across urine and oral fluid configurations, covering cocaine, methamphetamine, opiates, benzodiazepines, PCP, and additional analytes without generating a THC metabolite result. The SAFElife CLIA-waived urine cup lineup includes non-THC panel configurations that maintain full coverage of non-cannabis controlled substances. For employers running 10-panel programs, the SAFElife 10-panel C-Cup compact CLIA-waived urine drug test provides broad prescription drug coverage — benzodiazepines, methadone, oxycodone, barbiturates — that the standard 5-panel misses, without THC.
Path 2 — Use Oral Fluid Saliva Testing for Impairment-Based Scenarios
Oral fluid saliva testing detects the parent THC compound in saliva — not the stored metabolite detected by urine. The detection window for THC in oral fluid is typically up to 24 hours for casual use, closely tracking the period of actual impairment. That shorter window is precisely what makes oral fluid testing fall outside AB 2188's metabolite-based restrictions: the test speaks to recent use, not historical exposure.
For post-accident and reasonable suspicion testing — where the question is whether the employee was impaired near the time of an incident — oral fluid provides a defensible, impairment-proximate result. The non-THC 5-panel T-Square oral fluid saliva test and the non-THC 6-panel T-Square oral fluid saliva test — both with saturation indicator — give California employers observed, portable, adulteration-resistant collection for programs that need to screen for impairment without generating a THC metabolite result.
Path 3 — Retain THC Where the Exemption Applies
California construction employers, DOT-regulated employers, federal contractors, and employers with documented safety-sensitive positions retain the authority to test for THC and act on results. For those employers, the full SAFElife CLIA-waived urine cup collection — including THC-inclusive 5-panel, 10-panel, and expanded configurations — remains the right tool for pre-employment, random, post-accident, and reasonable suspicion programs.
✓ Which path fits your program? Construction employer with an active worksite? Retain THC on the panel. Staffing agency placing non-construction workers in California? Non-THC urine or oral fluid is the safer adaptation. Healthcare or logistics employer with both DOT and non-DOT employees? Consider running dual configurations — THC-inclusive for federally regulated roles, non-THC for the rest. For the full California drug testing framework, see our complete guide to California drug testing laws 2027.
What About Random and Reasonable Suspicion Testing?
California places meaningful restrictions on suspicionless random drug testing for private employers outside safety-sensitive classifications or federal regulatory mandates. Random programs for general private-sector workforces create litigation exposure without the support of either a documented safety-sensitive job classification or a federal requirement. California employers considering or expanding a random drug testing program should have it reviewed by qualified California employment counsel before implementation — particularly for THC testing, where AB 2188 adds an additional layer of restriction.
Reasonable suspicion testing remains available to California private employers. The critical requirements are consistent supervisor training, contemporaneous written documentation of observed behavior, and a clear written policy defining the threshold for a reasonable suspicion referral. For reasonable suspicion testing specifically, oral fluid saliva is the more defensible specimen type because a positive result speaks to recent use — not use that may have occurred days or weeks earlier — giving the employer a result that is factually connected to the documented observations.
This content is provided for general informational purposes only and does not constitute legal advice, regulatory guidance, or IRB or compliance consultation. DrugScreens.com supplies drug screening devices and does not provide laboratory services, medical diagnostics, IRB guidance, or drug testing program administration. Research teams should consult with their IRB, institutional compliance office, principal investigator, and qualified legal and regulatory counsel before implementing any drug screening protocol.
